<p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）在周三的午盘交易中股价创下 52 周新低。该股最低交易价为 3.96 美元，最后交易价为 3.8530 美元，成交量为 155008 股。该股此前收盘价为 4.53 美元。</p>
<h2>华尔街分析师观点</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的报告中重申了对中国苏轩堂药业股票的 “卖出（e+）” 评级。根据 MarketBeat 的数据，一位股票研究分析师对该股给予了卖出评级，该股的平均评级为 “卖出”。</p>
<p><strong>获取我们关于 SXTC 的最新报告</strong></p>
<h2>中国苏轩堂药业股票表现</h2>
<p>该公司的 50 日移动平均价格为 149.19 美元，200 日移动平均价格为 202.13 美元。</p>
<p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）最近一次发布财报是在 12 月 31 日。该公司报告季度每股收益（EPS）为（4.50）美元。该季度的营业收入为 31 万美元。</p>
<h2>机构资金流入和流出</h2>
<p>一家机构投资者最近增加了在中国苏轩堂药业股票中的持仓。根据其最近向 SEC 的披露，Virtu Financial LLC 在第三季度将其在中国苏轩堂药业（NASDAQ:SXTC - 免费报告）的持股增加了 107.5%。该机构投资者在此期间购买了 15013 股后，持有该公司 28983 股股票。根据其最近的 SEC 文件，Virtu Financial LLC 在中国苏轩堂药业的持股价值为 46000 美元。目前，5.02% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>中国苏轩堂药业公司简介</h2>
<p>（获取免费报告）</p>
<p>中国苏轩堂药业（NASDAQ:SXTC）是一家总部位于中国的生物制药公司，专注于基于肽的治疗药物的研究、开发、生产和商业化。该公司的产品线集中于针对肿瘤、内分泌和代谢疾病的新型治疗方案。通过利用专有的肽合成和制剂技术，中国苏轩堂旨在推进下一代生物制剂，以满足国内外市场未满足的医疗需求。</p>
<p>该公司的核心产品候选包括长效肽激素和肽药物偶联物，旨在提高患者的依从性和治疗效果。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而不是中国苏轩堂药业</li>
<li>华尔街对 USAU 持乐观态度，黄金创下新纪录！</li>
<li>雷·达里奥建议购买黄金。我说每月从中获利</li>
<li>用这四个简单步骤 “防止美联储影响” 你的银行账户</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在中国苏轩堂药业吗？</h2>
<p>在考虑投资中国苏轩堂药业之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而中国苏轩堂药业并不在名单上。</p>
<p>虽然中国苏轩堂药业目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

中国苏轩堂药业

美国制药 ETF - iShares

<p>中国苏轩堂药业（NASDAQ:SXTC）在交易中达到 52 周新低，报$3.96，收盘价为$3.8530。Weiss Ratings 维持 “卖出（e+）” 评级，分析师的平均评级为 “卖出”。该公司报告上个季度每股亏损$4.50，收入为$0.31 百万。机构投资者 Virtu Financial 增持 107.5%，持有 28,983 股，价值$46,000。中国苏轩堂专注于用于肿瘤和代谢疾病的肽类治疗，但目前并不被顶级分析师推荐投资</p>

<p>China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $3.96 and last traded at $3.8530, with a volume of 155008 shares traded. The stock had previously closed at $4.53.</p>
<div class="lb-trans"><p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）在周三的午盘交易中股价创下 52 周新低。该股最低交易价为 3.96 美元，最后交易价为 3.8530 美元，成交量为 155008 股。该股此前收盘价为 4.53 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of China SXT Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的报告中重申了对中国苏轩堂药业股票的 “卖出（e+）” 评级。根据 MarketBeat 的数据，一位股票研究分析师对该股给予了卖出评级，该股的平均评级为 “卖出”。</p>
</div><p><strong>Get Our Latest Report on SXTC</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 SXTC 的最新报告</strong></p>
</div><h2>China SXT Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>中国苏轩堂药业股票表现</h2>
</div><p>The firm has a 50 day moving average price of $149.19 and a two-hundred day moving average price of $202.13.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 149.19 美元，200 日移动平均价格为 202.13 美元。</p>
</div><p>China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) last posted its earnings results on Wednesday, December 31st. The company reported ($4.50) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter.</p>
<div class="lb-trans"><p>中国苏轩堂药业（NASDAQ:SXTC - 获取免费报告）最近一次发布财报是在 12 月 31 日。该公司报告季度每股收益（EPS）为（4.50）美元。该季度的营业收入为 31 万美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>An institutional investor recently raised its position in China SXT Pharmaceuticals stock. Virtu Financial LLC increased its holdings in China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Free Report) by 107.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,983 shares of the company's stock after buying an additional 15,013 shares during the period. Virtu Financial LLC's holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. 5.02% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一家机构投资者最近增加了在中国苏轩堂药业股票中的持仓。根据其最近向 SEC 的披露，Virtu Financial LLC 在第三季度将其在中国苏轩堂药业（NASDAQ:SXTC - 免费报告）的持股增加了 107.5%。该机构投资者在此期间购买了 15013 股后，持有该公司 28983 股股票。根据其最近的 SEC 文件，Virtu Financial LLC 在中国苏轩堂药业的持股价值为 46000 美元。目前，5.02% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>China SXT Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>中国苏轩堂药业公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>China SXT Pharmaceuticals Inc NASDAQ: SXTC is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.</p>
<div class="lb-trans"><p>中国苏轩堂药业（NASDAQ:SXTC）是一家总部位于中国的生物制药公司，专注于基于肽的治疗药物的研究、开发、生产和商业化。该公司的产品线集中于针对肿瘤、内分泌和代谢疾病的新型治疗方案。通过利用专有的肽合成和制剂技术，中国苏轩堂旨在推进下一代生物制剂，以满足国内外市场未满足的医疗需求。</p>
</div><p>The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.</p>
<div class="lb-trans"><p>该公司的核心产品候选包括长效肽激素和肽药物偶联物，旨在提高患者的依从性和治疗效果。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than China SXT Pharmaceuticals</li>
<li>Wall Street Turns Bullish on USAU as Gold Hits New Record!</li>
<li>Ray Dalio Says Buy Gold. I Say Get Paid Every Month From It</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是中国苏轩堂药业</li>
<li>华尔街对 USAU 持乐观态度，黄金创下新纪录！</li>
<li>雷·达里奥建议购买黄金。我说每月从中获利</li>
<li>用这四个简单步骤 “防止美联储影响” 你的银行账户</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>新法律：国会批准数字美元的设立？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in China SXT Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在中国苏轩堂药业吗？</h2>
</div><p>Before you consider China SXT Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资中国苏轩堂药业之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and China SXT Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄推荐给客户的股票，以便在更广泛的市场注意到之前购买……而中国苏轩堂药业并不在名单上。</p>
</div><p>While China SXT Pharmaceuticals currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然中国苏轩堂药业目前在分析师中被评为卖出，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

中国苏轩堂药业（NASDAQ:SXTC）股价创下 1 年来新低 - 以下是发生的情况